NEW YORK – 10x Genomics said on Monday that it expects fourth quarter revenues of approximately $184.0 million, up 18 percent year over year.
Instrument revenues were about $38.4 million, up 72 percent year over year, including $11.1 million from Chromium instruments and $27.2 million from spatial instruments. Consumables revenues were approximately $140.3 million, up 7 percent year over year, and consisted of $118.1 million in Chromium consumables and $22.2 million in spatial consumables. Services revenues were approximately $5.3 million, more than double the prior-year revenues during the same period.
For full-year 2023, 10x expects revenues of approximately $618.7 million, up 20 percent year over year.
Instrument revenues are expected to be about $123.5 million, up 71 percent year over year, and including $47.9 million from Chromium instruments and $75.6 million from spatial instruments. Consumables revenues were approximately $479.6 million, up 10 percent year over year, consisting of $420.3 million from Chromium instruments and $59.2 million from spatial instruments. Services revenues were approximately $15.7 million, up 86 percent over the prior year.
The firm noted that it has cumulatively sold more than 5,150 Chromium instruments, over 500 Visium instruments, and over 250 Xenium instruments.
Pacific Biosciences on Monday announced preliminary fourth quarter revenues of $58.4 million, more than double the amount it recorded a year ago.
Preliminary instrument revenues for the quarter are $35.1 million, up from $6.1 million in the prior-year period. Consumables revenues are expected to be $18.9 million, up from $16.7 million in Q4 of 2022, with 67 percent coming from PacBio's Revio sequencer. Service and other revenues are expected to be $4.4 million, compared to $4.6 million in the prior-year period.
For 2023, the firm expects revenues of $200.5 million, up 56 percent year over year. Consumables revenues are expected to be $63.4 million.
In a statement, the firm said it shipped a "record" number of sequencers in 2023, including 173 Revio systems — 44 of them in Q4 — and 20 Sequel IIe instruments. "The launch of the Revio system for scalable, accurate, long read sequencing and Onso, a short read sequencer with groundbreaking accuracy, enabled PacBio to reach more customers than ever before and, in the process, achieve record financial results," said CEO Christian Henry.
The firm ended the year with cash, cash equivalents, and investments of about $631 million.
Bionano Genomics said on Monday that it expects Q4 revenues in the range of $10.4 million to $10.7 million, representing year-over-year growth of between 27 percent and 30 percent.
The firm said it sold 7,980 flow cells in Q4, up 67 percent from 4,781 in the prior-year period, but it did not provide consumables revenues.
For 2023, Bionano expects revenue in the range of $35.8 million to $36.1 million, up 29 percent to 30 percent from the prior year.
The installed base of optical genome mapping systems grew to 326 by the end of 2023, compared to 240 at year-end 2022.
"2023 was a year in which we saw consistent progress in our business, and we ended the year with a lot of momentum across all facets of our business," President and CEO Erik Holmlin said in a statement.
As of Dec. 31, the firm had cash, cash equivalents, and available-for-sales securities of approximately $102.8 million, of which $36.1 million is subject to certain restrictions. The firm raised $11 million from at-the-market sales from Nov. 14 to Dec. 31 of 2023 and has raised an additional $2.9 million so far this year.
Standard BioTools on Monday reported approximately $28 million in preliminary fourth quarter revenues and about $106 million in 2023 preliminary revenues. Full-year revenues represent more than 10 percent year-over-year growth in core revenues, driven by more than 40 percent growth in instrument revenue.
The company also reported preliminary Q4 and 2023 revenues for SomaLogic, which merged with Standard BioTools last week. SomaLogic expects Q4 revenues of about $23 million and full-year revenues of approximately $86 million.
At the end of 2023, the combined company had approximately $550 million in cash, cash equivalents, and short-term investments.
"We are pleased that both companies delivered annual revenues above our stated targets, which we achieved in a challenging macroenvironment, and remain committed to building a scalable, profitable suite of differentiated life science tools and accelerating breakthroughs in healthcare," Standard BioTools President and CEO Michael Egholm said in a statement.
Singular Genomics Systems said on Sunday that it expects fourth quarter revenue of approximately $1.0 million, representing year-over-year growth of about 31 percent from $765,000. The firm shipped eight G4 sequencers in the quarter.
"We are proud of the momentum we built throughout 2023, increasing our installed base of instruments and recently launching two high-impact consumable kits: the F3 flow cells and Max Read flow cells," Singular CEO and Cofounder Drew Spaventa said in a statement.